BibTex RIS Kaynak Göster

Solifenacin induced dyskinesia

Yıl 2012, , - , 01.12.2012
https://doi.org/10.5799/ahinjs.01.2012.04.0218

Öz

Overactive bladder syndrome is a chronic condition characterised by urgency, with or without associated urge incontinence. Solifenacin succinate is a once daily, bladder selective antimuscarinic available. The recommended dose is 5 mg once daily and can be increased to 10 mg once daily if 5 mg is well tolerated. We report here a case with dyskinesia emerged following the use of solifenacin, and disappeared in a few days with stopping the agent.

Kaynakça

  • Wagg A, Wyndaele JJ, Sieber P. Efficacy and toler- ability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006;4(1):14-24.
  • Chancellor MB, Zinner N, Whitmore K, et al. Efficacy of solifenacin in patients previously treated with tolt- erodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther 2008;30(10):1766-81.
  • Basra R, Kelleher C. A review of solifenacin in the treat- ment of urinary incontinence. Ther Clin Risk Manag. 2008;4(1):117-28.
  • Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172(5):1919-24.
  • Suzuki M, Noguchi Y, Okutsu H, Ohtake A, Sasamata M. Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance re- sponse test. Eur J Pharmacol 2007;557(2-3):154-8.
  • Piecoro LT, Wermeling DP, Schmitt FA, Ashford JW. Seizures in patients receiving concomitant antimus- carinics and acetylcholinesterase inhibitor. Pharma- cotherapy 1998;18(5):1129-32.

Solifenazin\'e bağlı diskinezi

Yıl 2012, , - , 01.12.2012
https://doi.org/10.5799/ahinjs.01.2012.04.0218

Öz

Aşırı aktif mesane inkontinans olsun ya da olmasın urgency ile ilişkili kronik bir durumdur. Solifenazin günde tek doz kullanılan selektif antimuskarinik bir ajandır. Günde 5 mg olarak başlanır, tolere edilebilirse 10 mg\'a artırılabilir. Biz burada solifenazin kullanımı sonrası ortaya çıkan ve ilacın kesilmesini takiben birkaç gün içinde ortadan kaybolan diskinezili bir olguyu sunduk.

Kaynakça

  • Wagg A, Wyndaele JJ, Sieber P. Efficacy and toler- ability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006;4(1):14-24.
  • Chancellor MB, Zinner N, Whitmore K, et al. Efficacy of solifenacin in patients previously treated with tolt- erodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther 2008;30(10):1766-81.
  • Basra R, Kelleher C. A review of solifenacin in the treat- ment of urinary incontinence. Ther Clin Risk Manag. 2008;4(1):117-28.
  • Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172(5):1919-24.
  • Suzuki M, Noguchi Y, Okutsu H, Ohtake A, Sasamata M. Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance re- sponse test. Eur J Pharmacol 2007;557(2-3):154-8.
  • Piecoro LT, Wermeling DP, Schmitt FA, Ashford JW. Seizures in patients receiving concomitant antimus- carinics and acetylcholinesterase inhibitor. Pharma- cotherapy 1998;18(5):1129-32.
Toplam 6 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Olgu Sunumu
Yazarlar

Ersel Dağ Bu kişi benim

Burcu Azapoğlu Bu kişi benim

Turgut Deniz Bu kişi benim

Yayımlanma Tarihi 1 Aralık 2012
Yayımlandığı Sayı Yıl 2012

Kaynak Göster

APA Dağ, E., Azapoğlu, B., & Deniz, T. (2012). Solifenazin\’e bağlı diskinezi. Journal of Clinical and Experimental Investigations, 3(4). https://doi.org/10.5799/ahinjs.01.2012.04.0218
AMA Dağ E, Azapoğlu B, Deniz T. Solifenazin\’e bağlı diskinezi. J Clin Exp Invest. Aralık 2012;3(4). doi:10.5799/ahinjs.01.2012.04.0218
Chicago Dağ, Ersel, Burcu Azapoğlu, ve Turgut Deniz. “Solifenazin\’e bağlı Diskinezi”. Journal of Clinical and Experimental Investigations 3, sy. 4 (Aralık 2012). https://doi.org/10.5799/ahinjs.01.2012.04.0218.
EndNote Dağ E, Azapoğlu B, Deniz T (01 Aralık 2012) Solifenazin\’e bağlı diskinezi. Journal of Clinical and Experimental Investigations 3 4
IEEE E. Dağ, B. Azapoğlu, ve T. Deniz, “Solifenazin\’e bağlı diskinezi”, J Clin Exp Invest, c. 3, sy. 4, 2012, doi: 10.5799/ahinjs.01.2012.04.0218.
ISNAD Dağ, Ersel vd. “Solifenazin\’e bağlı Diskinezi”. Journal of Clinical and Experimental Investigations 3/4 (Aralık 2012). https://doi.org/10.5799/ahinjs.01.2012.04.0218.
JAMA Dağ E, Azapoğlu B, Deniz T. Solifenazin\’e bağlı diskinezi. J Clin Exp Invest. 2012;3. doi:10.5799/ahinjs.01.2012.04.0218.
MLA Dağ, Ersel vd. “Solifenazin\’e bağlı Diskinezi”. Journal of Clinical and Experimental Investigations, c. 3, sy. 4, 2012, doi:10.5799/ahinjs.01.2012.04.0218.
Vancouver Dağ E, Azapoğlu B, Deniz T. Solifenazin\’e bağlı diskinezi. J Clin Exp Invest. 2012;3(4).